Hims & Hers Health posted a revenue miss in the first quarter amid margin pressures.
The company is shifting away from compounded GLP-1 medications toward branded partnerships with Novo Nordisk and Eli Lilly. This change is expected to affect near-term margins while lowering legal risks associated with compounding.
Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
Rapporteret af AI
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
L’Oréal Group posted a 7.6% like-for-like revenue increase to €12.2 billion in the first quarter of fiscal 2026, exceeding analyst expectations. The results marked an acceleration from the previous quarter. CEO Nicolas Hieronimus credited innovation and e-commerce strength for global market share gains.
Rapporteret af AI
Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.